Drug Trial News

RSS

Intensive new combination therapy for ovarian cancer shows promising results

Researchers have found that more intensive chemotherapy maintenance for ovarian cancer could be beneficial for patients. The results of the study were presented at the ESMO Congress 2019 in Barcelona, Spain last weekend on the 28th of September.

30 Sep 2019

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.

30 Sep 2019

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer

With an estimated 570,000 cases and 311,000 deaths in 2018 worldwide, cervical cancer currently ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women.

30 Sep 2019

Study: Three-drug combination improves overall survival in patients with mCRC

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Sep 2019

Adding targeted therapy drug to standard treatment benefits aggressive breast cancer patients

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

29 Sep 2019

Combination of two immunotherapy drugs stops or reverses progression of advanced melanoma

A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced melanoma for five years or more in one in two patients, according to a study led by The Royal Marsden NHS Foundation Trust.

28 Sep 2019

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention and completed three months of dual antiplatelet therapy.

27 Sep 2019

Combination therapy may offer new therapeutic avenue for previously-treated NSCLC and kidney cancer patients

Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer and kidney cancer.

26 Sep 2019

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis.

26 Sep 2019

Investigational drug may offer new treatment option for patients with lung and kidney cancer

26 Sep 2019

New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

Stephenson Cancer Center Testing Drug for Prostate Cancer Patients on Active Surveillance OKLAHOMA CITY - Men who are diagnosed with low-risk prostate cancer usually opt for active surveillance - a monitoring of their cancer over time without undergoing treatments that would cause side effects.

20 Sep 2019

Novel gene therapy for glycogen storage disease shows positive results

At the Association for Glycogen Storage Disease's 41st Annual Conference, Dr. David Weinstein of UConn School of Medicine and Connecticut Children's presented his groundbreaking, one-year clinical trial results for the novel gene therapy treatment for glycogen storage disease.

20 Sep 2019

Prilenia's lead compound selected to participate in first-ever ALS platform trial

Prilenia, a newly formed biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that Pridopidine, its lead compound, has been selected as the first of three potential new treatments to be included in the launch of the first ever platform trial in amyotrophic lateral sclerosis (ALS).

19 Sep 2019

IMRT and cisplatin treatment meets acceptability criteria for PFS and swallowing-related QOL

Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer.

18 Sep 2019

Two uveitis drugs perform similarly in a head-to-head clinical trial

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

11 Sep 2019

New polypill cheaper, better at reducing cardiovascular disease

A new study from Beth Israel Deaconess Medical Center (BIDMC) has proved the cost-effectiveness and life-saving potential of the “polypill”: a single new pill which combines four commonly prescribed cardiovascular drugs into one to prevent a recurrent stroke or heart event in adult patients in low- and middle-income countries (LMIC).

5 Sep 2019

Ticagrelor reduces heart attacks and strokes for patients with diabetes

In late-breaking clinical trial results presented in a Hot Line Session today at the European Society of Cardiology Congress 2019, investigators from Brigham and Women's Hospital and Greater Paris University Hospitals - AP-HP/Université de Paris presented the results from The Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study, a clinical trial sponsored by AstraZeneca that evaluated whether adding ticagrelor to aspirin improves outcomes for patients with stable coronary artery disease and diabetes mellitus but without a history of heart attack or stroke.

3 Sep 2019

ARNI therapy trial misses target in heart failure, may have selective benefit only

Heart failure with preserved ejection fraction (HFpEF) is a common condition, affecting millions of people and resulting in significant illness and death. No effective treatments have been developed for this condition.

2 Sep 2019

Investigational drug reduces stuttering symptoms in open-label pilot study

A team led by a psychiatrist at the University of California, Riverside, has tested the orally administered investigational medication ecopipam on adults who stutter in an open-label, uncontrolled clinical trial and found that it reduced their stuttering symptoms from the start of therapy after eight weeks of dosing.

28 Aug 2019

Drug Trial News

Intensive new combination therapy for ovarian cancer shows promising results

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer

Study: Three-drug combination improves overall survival in patients with mCRC

Adding targeted therapy drug to standard treatment benefits aggressive breast cancer patients

Combination of two immunotherapy drugs stops or reverses progression of advanced melanoma

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

Combination therapy may offer new therapeutic avenue for previously-treated NSCLC and kidney cancer patients

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Investigational drug may offer new treatment option for patients with lung and kidney cancer

New clinical trial tests immunotherapy drug for prostate cancer patients on active surveillance

Novel gene therapy for glycogen storage disease shows positive results

Prilenia's lead compound selected to participate in first-ever ALS platform trial

IMRT and cisplatin treatment meets acceptability criteria for PFS and swallowing-related QOL

Two uveitis drugs perform similarly in a head-to-head clinical trial

New polypill cheaper, better at reducing cardiovascular disease

Ticagrelor reduces heart attacks and strokes for patients with diabetes

ARNI therapy trial misses target in heart failure, may have selective benefit only

Investigational drug reduces stuttering symptoms in open-label pilot study

Applying a Proteomics-based Approach to the Clinic

Proteomics & DIA Mass Spectroscopy in Neurodegenerative Disease Research

Lowering the Barriers to Automated Microscopy

Latest News